Format

Send to

Choose Destination
Liver Transpl. 2015 Apr;21(4):423-34. doi: 10.1002/lt.24080.

Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.

Author information

1
Department of Medicine, University of California San Francisco, San Francisco, CA.

Abstract

Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced because of HCV recurrence after transplant. Interferon-based antiviral treatment administered either before or after transplant to prevent or treat HCV recurrence, respectively, is limited because of poor tolerability and low efficacy. However, the treatment of HCV in the transplant setting is changing considerably with the availability of newer direct-acting antivirals and interferon-free regimens. This article will review the experience to date with treating HCV in the setting of cirrhosis and liver transplantation and will discuss the unique challenges encountered when this population is being treated.

PMID:
25604355
DOI:
10.1002/lt.24080
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center